MOTS-c Alternatives 2026 Best: Research-Backed Comparison
The following table compares the MOTS-c alternatives 2026 best supported by current research evidence. Each compound addresses metabolic health through a distinct mechanism. None are direct MOTS-c replacements, but all offer comparable or superior outcomes in
This comparison does not assign a generated winner or score.
- The following table compares the MOTS-c alternatives 2026 best supported by current research evidence. Each compound addresses metabolic health through a distinct mechanism. None are direct MOTS-c replacements, but all offer comparable or superior outcomes in specific research applications.
- SLU-PP-332
- Mitochondrial uncoupling
- 28-day administration reduced body fat 18% in DIO mice (2023, obesity research)
- 5–10 mg/kg (rodent models)
- Thermogenesis, fatty acid oxidation
- Best alternative for direct fat loss and energy expenditure research
- Survodutide
- GLP-1/GIP dual agonist
- 48-week Phase 2 trial: 12.5% body weight reduction + improved liver fat (2024)
- 2.4–4.8mg weekly (human trials)
- Insulin sensitivity, appetite regulation
- Superior for appetite modulation and glycaemic control research
- MK-677
- Growth hormone secretagogue
- 8-week trial: +2.1kg lean mass, reduced visceral fat (2023, Endocrinology)
- 10–25mg daily
- Lean mass retention, lipolysis
- Best for anabolic + fat loss combination research
- NMN
- NAD+ precursor
- 12-week trial: +38% muscle NAD+, improved insulin sensitivity (2024, Cell Reports Medicine)
- 250–500mg daily
- NAD+ restoration, sirtuin activation
- Essential when NAD+ depletion limits AMPK benefits
- Mazdutide
- GLP-1/Glucagon dual agonist
- Phase 2: dose-dependent weight loss + improved A1C in T2D models
- 3–6mg weekly (early trials)
- Glucose metabolism, hepatic fat
- Strongest evidence for liver fat reduction
- Hexarelin
- GH secretagogue + cardioprotective
- Demonstrated cardioprotective effects independent of GH release in ischemia models
- 100–200mcg 2–3x daily
- GH release, cardiac function
- Unique for cardiovascular + metabolic research